These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12540056)

  • 21. Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A.
    Martin L; Magnaudeix A; Esclaire F; Yardin C; Terro F
    Brain Res; 2009 Feb; 1252():66-75. PubMed ID: 19071093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Illite improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer׳s disease through Akt/CREB and GSK-3β phosphorylation in the brain.
    Jeon S; Park JE; Lee J; Liu QF; Jeong HJ; Pak SC; Yi S; Kim MH; Kim CW; Park JK; Kim GW; Koo BS
    J Ethnopharmacol; 2015 Feb; 160():69-77. PubMed ID: 25457987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models.
    Qing H; He G; Ly PT; Fox CJ; Staufenbiel M; Cai F; Zhang Z; Wei S; Sun X; Chen CH; Zhou W; Wang K; Song W
    J Exp Med; 2008 Nov; 205(12):2781-9. PubMed ID: 18955571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of Aldh2 (-/-) mice as an age-related model of cognitive impairment and Alzheimer's disease.
    D'Souza Y; Elharram A; Soon-Shiong R; Andrew RD; Bennett BM
    Mol Brain; 2015 Apr; 8():27. PubMed ID: 25910195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease.
    Herrmann N; Lanctôt KL; Rothenburg LS; Eryavec G
    Dement Geriatr Cogn Disord; 2007; 23(2):116-9. PubMed ID: 17148938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stratification of patients is the way to go to develop neuroprotective/disease-modifying drugs for Alzheimer's disease.
    Iqbal K; Chohan MO; Grundke-Iqbal I
    J Alzheimers Dis; 2008 Oct; 15(2):339-45. PubMed ID: 18953118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?
    Martinez A; Perez DI
    J Alzheimers Dis; 2008 Oct; 15(2):181-91. PubMed ID: 18953107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials.
    Chuang DM
    Ann N Y Acad Sci; 2005 Aug; 1053():195-204. PubMed ID: 16179524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology?
    Muyllaert D; Kremer A; Jaworski T; Borghgraef P; Devijver H; Croes S; Dewachter I; Van Leuven F
    Genes Brain Behav; 2008 Feb; 7 Suppl 1():57-66. PubMed ID: 18184370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
    J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease.
    Perez-Gonzalez R; Pascual C; Antequera D; Bolos M; Redondo M; Perez DI; Pérez-Grijalba V; Krzyzanowska A; Sarasa M; Gil C; Ferrer I; Martinez A; Carro E
    Neurobiol Aging; 2013 Sep; 34(9):2133-45. PubMed ID: 23582662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
    Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
    J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. L-3-n-butylphthalide reduces tau phosphorylation and improves cognitive deficits in AβPP/PS1-Alzheimer's transgenic mice.
    Peng Y; Hu Y; Xu S; Li P; Li J; Lu L; Yang H; Feng N; Wang L; Wang X
    J Alzheimers Dis; 2012; 29(2):379-91. PubMed ID: 22233765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resveratrol increases cerebral glycogen synthase kinase phosphorylation as well as protein levels of drebrin and transthyretin in mice: an exploratory study.
    Varamini B; Sikalidis AK; Bradford KL
    Int J Food Sci Nutr; 2014 Feb; 65(1):89-96. PubMed ID: 24020380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways.
    Hu JP; Xie JW; Wang CY; Wang T; Wang X; Wang SL; Teng WP; Wang ZY
    Brain Res Bull; 2011 May; 85(3-4):194-200. PubMed ID: 21435383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D.
    Sierksma AS; van den Hove DL; Pfau F; Philippens M; Bruno O; Fedele E; Ricciarelli R; Steinbusch HW; Vanmierlo T; Prickaerts J
    Neuropharmacology; 2014 Feb; 77():120-30. PubMed ID: 24067928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tau as a drug target in Alzheimer's disease.
    Gozes I
    J Mol Neurosci; 2002 Dec; 19(3):337-8. PubMed ID: 12540061
    [No Abstract]   [Full Text] [Related]  

  • 38. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing.
    Su Y; Ryder J; Li B; Wu X; Fox N; Solenberg P; Brune K; Paul S; Zhou Y; Liu F; Ni B
    Biochemistry; 2004 Jun; 43(22):6899-908. PubMed ID: 15170327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives].
    Blain H; Jouzeau JY; Blain A; Terlain B; Tréchot P; Touchon J; Netter P; Jeandel C
    Presse Med; 2000 Feb; 29(5):267-73. PubMed ID: 10701410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.